CMC Concepts

Analytical Method Transfer (AMT)

Analytical Method Transfer is the formal, documented process that qualifies a receiving unit (RU) to use an analytical procedure that originated in a transferring unit (TU)—demonstrating the RU has the knowledge and ability to perform the procedure as intended and to obtain reliable, comparable results. AMT is critical when moving testing between sites (including CDMOs/CROs) […]

Comparability: Managing Process Changes

A comparability assessment is the structured, risk-based process used to determine whether a biotechnological/biological product made before and after a manufacturing change remains comparable—i.e., has highly similar quality attributes with no adverse impact on quality, safety, or efficacy. Analytical testing is the foundation; when uncertainty remains, nonclinical and/or clinical bridging may be needed. Principles are […]

Data Integrity in the QC Lab

Data integrity means data are complete, consistent, and accurate across their lifecycle and are ALCOA: attributable, legible, contemporaneous, original/true copy, and accurate. Many authorities expect firms to extend this to ALCOA+ (complete, consistent, enduring, available). Failures are a frequent inspection focus; regulators expect effective, risk-based data governance embedded in the PQS. ALCOA+ essentials (what authorities […]

DS vs. DP: What’s the Difference?

In CMC, Drug Substance (DS) is the active material (API for small molecules; the active biological substance for biologics), and Drug Product (DP) is the finished dosage form in its final container-closure system that is administered to the patient. DS and DP have distinct manufacturing descriptions, control strategies, specifications, and stability programs. Regulatory submissions in […]

Qualifications Vs Validations

Analytical methods evolve along with product development. In early phases, methods only need to be qualified — proven “fit-for-purpose.” By late development, methods must be validated — comprehensively demonstrated to be reliable under all conditions. The transition from qualification to validation is one of the most important milestones in CMC development. Development Stage Method Status […]

Reference Standards: The Cornerstone of Control

A reference standard (reference material) is an appropriately characterized, qualified material used as the benchmark for calibration, control, and comparison of analytical measurements across the product lifecycle. For new biologics, sponsors typically establish an in-house primary reference material from lot(s) representative of production and clinical materials, then qualify working (secondary) standards against it to maintain […]

Setting Specifications & Justification of Acceptance Criteria

A specification is the approved list of tests, references to analytical procedures, and acceptance criteria that a drug substance or product must meet to be acceptable for its intended use. Specifications are proposed and justified by the manufacturer and approved by regulatory authorities as conditions of approval; they are one element of the total control […]

Stability-Indicating Methods & Stability Studies

Executive summary Establishing a labeled shelf life requires two tightly linked elements: (1) a stability-indicating analytical approach (validated or phase-appropriately qualified) that can assess the product in the presence of degradants/changes, and (2) a formal stability program on representative batches under ICH-defined storage conditions. For biologics, there is no single universal test; sponsors propose a […]

The Analytical Method Lifecycle

Executive SummaryThe analytical procedure lifecycle is a modern, holistic framework (USP ⟨1220⟩) for design, qualification, and ongoing verification of analytical methods. Rather than treating a method as “validated once,” it treats it as a managed process that must remain fit for purpose over its entire lifespan. This lifecycle approach aligns with Quality by Design (QbD) […]